MaxCyte, Inc. (MXCT) — Analyst outlook / Analyst consensus target is. Based on 6 analyst ratings, the consensus is bullish — 4 Buy, 2 Hold.
The consensus price target is $6.00, representing an upside of 609.9% from the current price $0.85.
Analysts estimate Earnings Per Share (EPS) of $-0.41 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.39 vs est $-0.41 (beat +5.1%). 2025: actual $-0.42 vs est $-0.39 (missed -7.2%). Analyst accuracy: 94%.
MXCT Stock — 12-Month Price Forecast
$6.00
▲ +609.89% Upside
Average Price Target
Based on 6 Wall Street analysts offering 12-month price targets for MaxCyte, Inc., the price target is $6.00.
The average price target represents a +609.89% change from the last price of $0.85.
MXCT Analyst Ratings
Buy
Based on 6 analysts giving stock ratings to MaxCyte, Inc. in the past 3 months
EPS Estimates — MXCT
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.39
vs Est –$0.41
▲ 5.4% off
2025
Actual –$0.42
vs Est –$0.39
▼ 6.7% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — MXCT
96%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.039B
vs Est $0.038B
▲ 1.2% off
2025
Actual $0.033B
vs Est $0.035B
▼ 6.3% off
Revenue Trend
Revenue has declined over the period shown. Analysts expect stable revenue going forward.
